The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
News|Articles|February 1, 2002
- Pharmaceutical Technology-02-02-2002
- Volume 26
- Issue 2
Available Guidance and Best Practices for Conducting Forced Degradation Studies
Participants at a Pharmaceutical Research and Manufacturers of America workshop share their views about the acceptable analytical practices of conducting forced degradation studies.
Advertisement
Articles in this issue
almost 25 years ago
Using Earned-Value Analysis to Better Manage Projectsalmost 25 years ago
Microbial Bioburden on Oral Solid Dosage Formsalmost 25 years ago
Modernizing Pharmaceutical Manufacturingalmost 25 years ago
The Role of Computational Fluid Dynamics in the Pharmaceutical Industryalmost 25 years ago
Outsourcing OutlookAdvertisement
Related to this article
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
The PharmTech AI Pulse Check panel discusses why MHRA and FDA oversight of pharma AI continues past go-live, and who validates the regulators' own AI.
USP data show fewer US drug shortages but longer ones, averaging 5+ years. Drug shortages are an incentive problem, not a manufacturing mystery.
The pharmaceutical supply chain is a complex system with high stakes. USP provides insights on how it is helping industry navigate global disruptions and procurement issues.
Jaenisch, Muraru, and Pandey discuss how regulators will audit pharma against its own AI policies and ways QA and regulatory teams can build defensible, inspection-ready AI practices.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
2
Why Impurity Deficiencies Keep Repeating: AAPS PharmSci 360 2026
3
Why Drug Shortages Average 5+ Years: PharmTech Explained
4
ADCs, Degraders, Agonists: 4 Deals CMC Teams Should Track
5